Abstract
Objective To examine whether sleep and pain-related traits have a causal effect on the risk of neurodegeneration.
Design Two-sample Mendelian randomization using an inverse-variance weighted (IVW) estimate of the summary effect estimates.
Setting Genetic data on sleep and pain-related traits and neurodegenerative disorders (NDD) from various cohorts comprising individuals predominantly of European ancestry.
Participants Participants from the International Sleep Genetic Epidemiology Consortium (ISGEC), UK Biobank sleep and chronotype research group, International Genomics of Alzheimer’s patients (IGAP), project MinE, International Age-related Macular Degeneration Consortium (IAMDGC), International Multiple Sclerosis Genetics Consortium (IMSGC), International Parkinson’s Disease Genomics Consortium (IPDGC)
Exposures Self-reported chronotype (CHR), morning preference (MP), insomnia symptoms (INS), sleep duration (SP), short sleep (SS), long sleep (LS), and multisite chronic pain (MCP)
Main outcome measures Age-related macular degeneration (AMD), Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS), and Parkinson’s disease (PD)
Results We considered a threshold of P=0.00142 as significant accounting for multiple testing, and P<0.05 was considered to be suggestive evidence for a potential association. Using direct MR, MP was observed as the strongest risk factor for AMD (ORIVW = 1.19, 95% CI 1.08, 1.32, P = 0.00073). We observed suggestive evidence of influence of different sleep traits on neurodegeneration: CHR on AMD (ORIVW = 1.27, 95% CI 1.08, 1.49, P = 0.0034), SS on AD (ORIVW 1.26, 95% CI 1.08, 1.46, P = 0.0044), and INS on ALS (ORIVW 1.55, 95% CI 1.12, 2.14, P = 0.0123). The association of SS with AD was, however, lost after the exclusion of overlapping UKB samples. Using pain as exposure, our study failed to observe any role of pain in neurodegeneration. Results were largely robust to reverse causal analyses and sensitivity analyses accounting for horizontal pleiotropy.
Conclusions Our study highlighted the role of morning preference as a risk factor for AMD and provided suggestive evidence of different sleep traits on a wide spectrum of neurodegenerative diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge the study participants and investigators of International Genomics of Alzheimers patients (IGAP), International Parkinsons Disease Genomics Consortium (IPDGC), project MinE, International Multiple Sclerosis Genetics Consortium (IMSGC), International Sleep Genetic Epidemiology Consortium (ISGEC), UK Biobank, UK Biobank sleep and chronotype research group for sharing the summary statistics on their GWAS datasets. We also acknowledge UK biobank resources under Application number 65949. This study is, in part, supported by the EU Joint Programme - Neurodegenerative Diseases Research (JPND) project under the aegis of JPND (www.jpnd.eu) through Germany, BMBF, funding code 01ED1406. M.S. is further funded by the Michael J Fox Foundation, USA Genetic Diversity in PD Program: GAP-India Grant ID: 17473. and also supported by the grants from the German Research Council (DFG/SH 599/6-1 to M.S.), MSA Coalition, and Michael J Fox Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable as it used publically available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data is publicly available.
